SUPPLEMENT

Q3 2022 — Financial disclosures

Q3 2022PDF · 10 pages1.0 MB
Merck & Co., Inc.
Financial Highlights Package
Third Quarter 2022
Table of Contents
Table 1: GAAP P&L....................................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2
Table 2a: GAAP to Non-GAAP Reconciliation 3Q22 and Sept YTD 22.......3
Table 2b: GAAP to Non-GAAP Reconciliation 3Q21 and Sept YTD 21.......4
Table 3: Sales - Current Year and Prior Year by Quarter...........................5
Table 3a: Sales – U.S. / Ex- U.S. 3Q22........................................................6
Table 3b: Sales – U.S. / Ex- U.S. Sept YTD 22...........................................7
Table 3c: Sales – Pharmaceutical Geographic Split....................................8
Table 4: Other (Income) Expense .............................................................9

-- 1 of 10 --

Sales 	14,959	$ 	13,154	$ 	14% 	45,453	$ 	35,183	$ 	29%
Costs, Expenses and Other
Cost of sales 	3,934 	3,450 	14% 	13,530 	9,752 	39%
Selling, general and administrative 	2,520 	2,336 	8% 	7,355 	6,804 	8%
Research and development 	4,399 	2,445 	80% 	9,773 	9,177 	6%
Restructuring costs 	94 	107 	-12% 	288 	487 	-41%
Other (income) expense, net 	429 	(450) 	* 	1,576 	(1,007) 	*
Income from Continuing Operations Before Taxes 	3,583 	5,266 	-32% 	12,931 	9,970 	30%
Income Tax Provision 	330 	695 	1,423 	1,436
Net Income from Continuing Operations 	3,253 	4,571 	-29% 	11,508 	8,534 	35%
Less: Net Income Attributable to Noncontrolling Interests 	5 	4 	6 	9
Net Income from Continuing Operations Attributable to Merck &
Co., Inc. 3,248 	4,567 	-29% 	11,502 	8,525 	35%
Income from Discontinued Operations, Net of Taxes and Amounts
Attributable to Noncontrolling Interests - 	- 	0% 	- 	766 	*
Net Income Attributable to Merck & Co., Inc. 	3,248	$ 	4,567	$ 	-29% 	11,502	$ 	9,291	$ 	24%
Basic Earnings per Common Share Attributable to Merck & Co., Inc.
Common Shareholders:
Income from Continuing Operations 	1.28	$ 	1.81	$ 	-29% 	4.55	$ 	3.37	$ 	35%
Income from Discontinued Operations 	- 	- 	0% 	- 	0.30 	*
Net Income 	1.28	$ 	1.81	$ 	-29% 	4.55	$ 	3.67	$ 	24%
Earnings per Common Share Assuming Dilution Attributable to
Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations 	1.28	$ 	1.80	$ 	-29% 	4.53	$ 	3.36	$ 	35%
Income from Discontinued Operations 	- 	- 	0% 	- 	0.30 	*
Net Income 	1.28	$ 	1.80	$ 	-29% 	4.53	$ 	3.66	$ 	24%
Average Shares Outstanding 	2,533 	2,530 	2,531 	2,531
Average Shares Outstanding Assuming Dilution 	2,542 	2,536 	2,540 	2,539
Tax Rate from Continuing Operations 	9.2% 	13.2% 	11.0% 	14.4%
* 100% or greater
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
GAAP
% Change
GAAP
% Change
3Q22
On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new,
independent, publicly traded company named Organon & Co. (Organon). The historical results of the businesses that were contributed to Organon in the
spin-off are excluded from sales and expenses and reflected as discontinued operations in the company’s Consolidated Statement of Income provided
below.
3Q21 Sep YTD
2022
Sep YTD
2021
1

-- 2 of 10 --

Sales 	15,901	$ 	14,593	$ 	14,959	$ 	45,453	$ 	10,627	$ 	11,402	$ 	13,154	$ 	35,183	$ 	13,521	$ 	48,704	$ 	14% 	29%
Costs, Expenses and Other
Cost of sales 	5,380 	4,216 	3,934 	13,530 	3,199 	3,104 	3,450 	9,752 	3,873 	13,626 	14% 	39%
Selling, general and administrative 	2,323 	2,512 	2,520 	7,355 	2,187 	2,281 	2,336 	6,804 	2,830 	9,634 	8% 	8%
Research and development 	2,576 	2,798 	4,399 	9,773 	2,412 	4,321 	2,445 	9,177 	3,068 	12,245 	80% 	6%
Restructuring costs 	53 	142 	94 	288 	297 	82 	107 	487 	174 	661 	-12% 	-41%
Other (income) expense, net 	708 	438 	429 	1,576 	(455) 	(103) 	(450) 	(1,007) 	(333) 	(1,341) 	* 	*
Income from Continuing Operations Before Taxes 	4,861 	4,487 	3,583 	12,931 	2,987 	1,717 	5,266 	9,970 	3,909 	13,879 	-32% 	30%
Income Tax Provision 	554 	538 	330 	1,423 	238 	503 	695 	1,436 	85 	1,521
Net Income from Continuing Operations 	4,307 	3,949 	3,253 	11,508 	2,749 	1,214 	4,571 	8,534 	3,824 	12,358 	-29% 	35%
Less: Net (Loss) Income Attributable to Noncontrolling Interests 	(3) 	5 	5 	6 	4 	1 	4 	9 	4 	13
Net Income from Continuing Operations Attributable to Merck &
Co., Inc.
4,310 	3,944 	3,248 	11,502 	2,745 	1,213 	4,567 	8,525 	3,820 	12,345 	-29% 	35%
Income (Loss) from Discontinued Operations, Net of Taxes and
Amounts Attributable to Noncontrolling Interests
- 	- 	- 	- 	434 	332 	- 	766 	(62) 	704 	0% 	*
Net Income Attributable to Merck & Co., Inc. 	4,310	$ 	3,944	$ 	3,248	$ 	11,502	$ 	3,179	$ 	1,545	$ 	4,567	$ 	9,291	$ 	3,758	$ 	13,049	$ 	-29% 	24%
Basic Earnings (Loss) per Common Share Attributable to Merck
& Co., Inc. Common Shareholders:
Income from Continuing Operations 	1.70	$ 	1.56	$ 	1.28	$ 	4.55	$ 	1.08	$ 	0.48	$ 	1.81	$ 	3.37	$ 	1.51	$ 	4.88	$ 	-29% 	35%
Income (Loss) from Discontinued Operations 	- 	- 	- 	- 	0.17 	0.13 	- 	0.30 	(0.02) 	0.28 	0% 	*
Net Income 	1.70	$ 	1.56	$ 	1.28	$ 	4.55	$ 	1.26	$ 	0.61	$ 	1.81	$ 	3.67	$ 	1.49	$ 	5.16	$ 	-29% 	24%
Earnings (Loss) per Common Share Assuming Dilution
Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations 	1.70	$ 	1.55	$ 	1.28	$ 	4.53	$ 	1.08	$ 	0.48	$ 	1.80	$ 	3.36	$ 	1.51	$ 	4.86	$ 	-29% 	35%
Income (Loss) from Discontinued Operations 	- 	- 	- 	- 	0.17 	0.13 	- 	0.30 	(0.02) 	0.28 	0% 	*
Net Income 	1.70	$ 	1.55	$ 	1.28	$ 	4.53	$ 	1.25	$ 	0.61	$ 	1.80	$ 	3.66	$ 	1.48	$ 	5.14	$ 	-29% 	24%
Average Shares Outstanding 	2,528 	2,531 	2,533 	2,531 	2,531 	2,533 	2,530 	2,531 	2,527 	2,530
Average Shares Outstanding Assuming Dilution 	2,537 	2,540 	2,542 	2,540 	2,541 	2,540 	2,536 	2,539 	2,535 	2,538
Tax Rate from Continuing Operations 	11.4% 	12.0% 	9.2% 	11.0% 	8.0% 	29.3% 	13.2% 	14.4% 	2.2% 	11.0%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
% Change
3Q 	Sep YTD
2022
2Q 	3Q 	Sep YTD	1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
2021
Sep YTD
Table 1a
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
2

-- 3 of 10 --

Third Quarter
Cost of sales 	3,934	$ 	446 	54 	500 	3,434	$
Selling, general and administrative 	2,520 	22 	26 	48 	2,472
Research and development 	4,399 	902 	1 	903 	3,496
Restructuring costs 	94 	94 	94 	-
Other (income) expense, net 	429 	(26) 	350 	324 	105
Income from Continuing Operations Before Taxes 	3,583 	(1,344) 	(175) 	(350) 	(1,869) 	5,452
Income Tax Provision (Benefit) 	330 	(302) (3) (35) (3) (77) (3) (414) 	744
Net Income from Continuing Operations 	3,253 	(1,042) 	(140) 	(273) 	(1,455) 	4,708
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 3,248 	(1,042) 	(140) 	(273) 	(1,455) 	4,703
Earnings per Common Share Assuming Dilution from
Continuing Operations 1.28	$ 	(0.40) 	(0.06) 	(0.11) 	(0.57) 	1.85	$
Tax Rate 	9.2% 	13.6%
Sep YTD
Cost of sales 	13,530	$ 	1,577 	167 	1,744 	11,786	$
Selling, general and administrative 	7,355 	137 	74 	211 	7,144
Research and development 	9,773 	936 	30 	966 	8,807
Restructuring costs 	288 	288 	288 	-
Other (income) expense, net 	1,576 	(138) 	1,268 	1,130 	446
Income from Continuing Operations Before Taxes 	12,931 	(2,512) 	(559) 	(1,268) 	(4,339) 	17,270
Income Tax Provision (Benefit) 	1,423 	(587) (3) (97) (3) (281) (3) (965) 	2,388
Net Income from Continuing Operations 	11,508 	(1,925) 	(462) 	(987) 	(3,374) 	14,882
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 11,502 	(1,925) 	(462) 	(987) 	(3,374) 	14,876
Earnings per Common Share Assuming Dilution from
Continuing Operations 4.53	$ 	(0.76) 	(0.18) 	(0.39) 	(1.33) 	5.86	$
Tax Rate 	11.0% 	13.8%
Only the line items that are affected by non-GAAP adjustments are shown.
MERCK & CO., INC.
THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2022 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and
trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for
or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration,
transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses for the third quarter and nine month period primarily reflect
$887 million of intangible asset impairment charges related to the ArQule, Inc. acquisition and expenses for the amortization of intangible assets. Amounts included in other (income) expense, net,
for the third quarter and nine month period primarily reflect royalty income and a decrease in the estimated fair value measurement of liabilities for contingent consideration related to the prior
termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring
programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
GAAP Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)
(Income) Loss from
Investments in Equity
Securities
Adjustment Subtotal
3

-- 4 of 10 --

Third Quarter
Cost of sales 	3,450	$ 	346 	48 	394 	3,056	$
Selling, general and administrative 	2,336 	61 	5 	66 	2,270
Research and development 	2,445 	48 	8 	56 	2,389
Restructuring costs 	107 	107 	107 	-
Other (income) expense, net 	(450) 	(10) 	(684) 	(694) 	244
Income from Continuing Operations Before Taxes 	5,266 	(445) 	(168) 	684 	71 	5,195
Income Tax Provision (Benefit) 	695 	(96) (4) (26) (4) 151 (4) 29 	666
Net Income from Continuing Operations 	4,571 	(349) 	(142) 	533 	42 	4,529
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 4,567 	(349) 	(142) 	533 	42 	4,525
Earnings per Common Share Assuming Dilution from
Continuing Operations 1.80	$ 	(0.13) 	(0.06) 	0.21 	0.02 	1.78	$
Tax Rate 	13.2% 	12.8%
Sep YTD
Cost of sales 	9,752	$ 	1,188 	113 	225 (3) 1,526 	8,226	$
Selling, general and administrative 	6,804 	96 	9 	105 	6,699
Research and development 	9,177 	82 	21 	103 	9,074
Restructuring costs 	487 	487 	487 	-
Other (income) expense, net 	(1,007) 	79 	(1,503) 	(1,424) 	417
Income from Continuing Operations Before Taxes 	9,970 	(1,445) 	(630) 	1,503 	(225) 	(797) 	10,767
Income Tax Provision (Benefit) 	1,436 	(283) (4) (82) (4) 331 (4) (257) (4) (291) 	1,727
Net Income from Continuing Operations 	8,534 	(1,162) 	(548) 	1,172 	32 	(506) 	9,040
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 8,525 	(1,162) 	(548) 	1,172 	32 	(506) 	9,031
Earnings per Common Share Assuming Dilution from
Continuing Operations 3.36	$ 	(0.46) 	(0.22) 	0.46 	0.02 	(0.20) 	3.56	$
Tax Rate 	14.4% 	16.0%
Only the line items that are affected by non-GAAP adjustments are shown.
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management
believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP
measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-
GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other
costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense,
net, for the third quarter and nine month period primarily reflect an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint
venture. Additionally, the nine month period also includes a loss on a forward exchange contract entered into in conjunction with the Organon spin-off. Amount included in other (income) expense, net, for the nine month
period was partially offset by royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Represents charges for the discontinuation of COVID-19 development programs.
(4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items for the nine month period also includes a
$207 million net tax benefit related to the settlement of certain federal income tax matters.
Adjustment Subtotal 	Non-GAAP
MERCK & CO., INC.
THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are
excluded from the financial information provided below.
GAAP Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)
(Income) Loss from
Investments in Equity
Securities
Certain Other Items
Table 2b
In 2022, the company changed the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck’s non-GAAP results excluded expenses for upfront and milestone
payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions, to the extent the
charges were considered by the company to be significant to the results of a particular period (as well as any related adjustments recorded in a subsequent period). Beginning in 2022, Merck’s
non-GAAP results no longer exclude charges related to these items. Results for 2021 have been recast to conform to the new presentation.
4

-- 5 of 10 --

1Q 	2Q 	3Q 	Sep YTD 	1Q 	2Q 	3Q 	Sep YTD 	4Q 	Full Year 	Nom % 	Ex-Exch % 	Nom % 	Ex-Exch %
TOTAL SALES (1) $15,901 	$14,593 	$14,959 	$45,453 	$10,627 	$11,402 	$13,154 	$35,183 	$13,521 	$48,704 	14 	18 	29 	32
PHARMACEUTICAL 	14,107 	12,756 	12,963 	39,826 	9,238 	9,980 	11,496 	30,714 	12,039 	42,754 	13 	19 	30 	35
Oncology
Keytruda 	4,809 	5,252 	5,426 	15,487 	3,899 	4,176 	4,534 	12,609 	4,577 	17,186 	20 	26 	23 	28
Alliance Revenue – Lynparza (2) 266 	275 	284 	825 	228 	248 	246 	721 	268 	989 	16 	23 	14 	20
Alliance Revenue – Lenvima (2) 227 	231 	202 	660 	130 	181 	188 	498 	206 	704 	7 	11 	33 	36
Alliance Revenue – Reblozyl (3) 52 	33 	39 	124 	17 	17 	* 	* 	* 	*
Vaccines (4)
Gardasil / Gardasil 9 	1,460 	1,674 	2,294 	5,428 	917 	1,234 	1,993 	4,144 	1,528 	5,673 	15 	20 	31 	35
ProQuad / M-M-R II / Varivax 	470 	578 	668 	1,716 	449 	516 	661 	1,626 	509 	2,135 	1 	3 	6 	7
RotaTeq 	216 	173 	256 	644 	158 	208 	227 	593 	213 	807 	12 	16 	9 	11
Pneumovax 23 	173 	153 	131 	457 	171 	152 	277 	600 	292 	893 	-53 	-50 	-24 	-21
Vaqta 	36 	35 	64 	134 	34 	56 	48 	138 	41 	179 	33 	34 	-3 	-2
Hospital Acute Care
Bridion 	395 	426 	423 	1,244 	340 	387 	369 	1,096 	436 	1,532 	15 	22 	13 	19
Prevymis 	94 	103 	114 	310 	82 	93 	96 	270 	100 	370 	19 	29 	15 	22
Dificid 	52 	66 	77 	196 	27 	34 	54 	115 	60 	175 	42 	42 	70 	70
Primaxin 	58 	64 	63 	185 	65 	60 	70 	194 	65 	259 	-9 	-5 	-5 	-3
Noxafil 	57 	60 	62 	180 	67 	66 	64 	197 	62 	259 	-3 	5 	-9 	-3
Invanz 	52 	46 	50 	148 	57 	48 	53 	157 	45 	202 	-7 	-1 	-6 	-1
Cancidas 	53 	42 	43 	138 	57 	54 	56 	168 	45 	212 	-24 	-19 	-18 	-15
Zerbaxa 	30 	46 	43 	120 	(8) 	(1) 	(2) 	(11) 	10 	(1) 	* 	* 	* 	*
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 72 	98 	88 	258 	74 	74 	100 	248 	94 	342 	-12 	-12 	4 	4
Adempas (6) 61 	63 	57 	181 	55 	74 	59 	188 	63 	252 	-5 	12 	-4 	8
Virology
Lagevrio 	3,247 	1,177 	436 	4,859 	952 	952 	* 	* 	* 	*
Isentress / Isentress HD 	158 	147 	161 	466 	209 	192 	189 	590 	178 	769 	-15 	-11 	-21 	-17
Neuroscience
Belsomra 	69 	69 	62 	199 	79 	78 	81 	238 	80 	318 	-24 	-12 	-16 	-7
Immunology
Simponi 	186 	181 	173 	540 	214 	202 	203 	619 	206 	825 	-15 	-2 	-13 	-2
Remicade 	61 	53 	49 	163 	85 	75 	73 	233 	67 	299 	-33 	-22 	-30 	-21
Diabetes (7)
Januvia 	779 	756 	717 	2,252 	809 	784 	852 	2,445 	878 	3,324 	-16 	-10 	-8 	-3
Janumet 	454 	476 	417 	1,347 	486 	477 	487 	1,449 	514 	1,964 	-14 	-7 	-7 	-1
Other Pharmaceutical (8) 520 	479 	564 	1,565 	554 	512 	518 	1,589 	533 	2,118 	9 	17 	-1 	3
ANIMAL HEALTH 	1,482 	1,467 	1,371 	4,320 	1,418 	1,472 	1,417 	4,307 	1,261 	5,568 	-3 	4 	- 	6
Livestock 	832 	826 	829 	2,486 	819 	821 	864 	2,503 	791 	3,295 	-4 	4 	-1 	6
Companion Animals 	650 	641 	542 	1,834 	599 	651 	553 	1,804 	470 	2,273 	-2 	4 	2 	6
Other Revenues (9) 312 	370 	625 	1,307 	(29) 	(50) 	241 	162 	221 	382 	159 	41 	* 	*
* 200% or greater
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $1,305 million, $1,300 million and $1,231 million in the first, second and third quarter of 2022, respectively, and $1,363 million, $1,330 million, $1,417 million and $1,475
million in the first, second, third and fourth quarter of 2021, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related
to the receipt of upfront and milestone payments for out-licensed products were $114 million, $32 million and $10 million in the first, second and third quarter of 2022, respectively, and $56 million, $135
million and $27 million in the first, third and fourth quarter of 2021, respectively.
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties and a milestone payment.
(4) Total Vaccines sales were $2,481 million, $2,709 million and $3,552 million in the first, second and third quarter of 2022, respectively, and $1,809 million, $2,293 million, $3,315 million and $2,715
million in the first, second, third and fourth quarter of 2021, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
2022 	2021 	3Q 	September YTD
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
5

-- 6 of 10 --

3Q 2022 	3Q 2021 	% Change 	3Q 2022 	3Q 2021 	% Change 	3Q 2022 	3Q 2021 	% Change
TOTAL SALES (1) $14,959 	$13,154 	14 	$7,322 	$6,276 	17 	$7,637 	$6,878 	11
PHARMACEUTICAL 	12,963 	11,496 	13 	6,620 	5,670 	17 	6,343 	5,826 	9
Oncology
Keytruda 	5,426 	4,534 	20 	3,331 	2,580 	29 	2,095 	1,954 	7
Alliance Revenue - Lynparza (2) 284 	246 	16 	144 	129 	12 	140 	117 	20
Alliance Revenue - Lenvima (2) 202 	188 	7 	142 	114 	25 	60 	74 	-19
Alliance Revenue - Reblozyl (3) 39 	* 	32 	* 	7 	*
Vaccines (4)
Gardasil / Gardasil 9 	2,294 	1,993 	15 	957 	839 	14 	1,337 	1,154 	16
ProQuad / M-M-R II / Varivax 	668 	661 	1 	532 	537 	-1 	136 	125 	9
RotaTeq 	256 	227 	12 	154 	135 	13 	102 	92 	11
Pneumovax 23 	131 	277 	-53 	68 	181 	-62 	63 	97 	-35
Vaqta 	64 	48 	33 	27 	32 	-16 	36 	16 	134
Hospital Acute Care
Bridion 	423 	369 	15 	233 	181 	29 	190 	188 	1
Prevymis 	114 	96 	19 	49 	39 	26 	64 	57 	14
Dificid 	77 	54 	42 	72 	52 	37 	6 	2 	146
Primaxin 	63 	70 	-9 	-57 	63 	69 	-9
Noxafil 	62 	64 	-3 	13 	19 	-30 	49 	45 	8
Invanz 	50 	53 	-7 	2 	(2) 	-174 	48 	55 	-14
Zerbaxa 	43 	(2) 	* 	24 	(1) 	* 	19 	(1) 	*
Cancidas 	43 	56 	-24 	1 	1 	81 	42 	56 	-25
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 88 	100 	-12 	85 	73 	17 	3 	27 	-90
Adempas (6) 57 	59 	-5 	57 	59 	-5
Virology
Lagevrio 	436 	* 	- 	436 	*
Isentress / Isentress HD 	161 	189 	-15 	68 	77 	-12 	93 	112 	-17
Neuroscience
Belsomra 	62 	81 	-24 	20 	23 	-13 	42 	58 	-28
Immunology
Simponi 	173 	203 	-15 	173 	203 	-15
Remicade 	49 	73 	-33 	49 	73 	-33
Diabetes (7)
Januvia 	717 	852 	-16 	332 	365 	-9 	385 	487 	-21
Janumet 	417 	487 	-14 	90 	86 	4 	327 	401 	-18
Other Pharmaceutical (8) 564 	518 	9 	244 	210 	16 	321 	306 	5
ANIMAL HEALTH 	1,371 	1,417 	-3 	475 	467 	2 	896 	951 	-6
Livestock 	829 	864 	-4 	186 	190 	-2 	643 	675 	-5
Companion Animals 	542 	553 	-2 	289 	277 	4 	253 	276 	-8
Other Revenues (9) 625 	241 	159 	227 	139 	63 	398 	101 	*
* 200% or greater
Sum of U.S. plus international may not equal global due to rounding.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the
receipt of upfront and milestone payments for out-licensed products were $10 million in the third quarter of 2022 and $135 million in the third quarter of 2021.
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $3,552 million in the third quarter of 2022 and $3,315 million in the third quarter of 2021.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $1,231 million in the third quarter of 2022 and $1,417 million in the third quarter of 2021.
(8) Includes Pharmaceutical products not individually shown above.
Table 3a
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
THIRD QUARTER 2022
(AMOUNTS IN MILLIONS)
(UNAUDITED)
6

-- 7 of 10 --

September YTD
2022
September YTD
2021 	% Change
September YTD
2022
September YTD
2021 	% Change
September YTD
2022
September YTD
2021 	% Change
TOTAL SALES (1) $45,453 	$35,183 	29 	$20,927 	$16,166 	29 	$24,526 	$19,017 	29
PHARMACEUTICAL 	39,826 	30,714 	30 	19,119 	14,611 	31 	20,707 	16,103 	29
Oncology
Keytruda 	15,487 	12,609 	23 	9,307 	7,108 	31 	6,180 	5,501 	12
Alliance Revenue - Lynparza (2) 825 	721 	14 	427 	371 	15 	397 	350 	14
Alliance Revenue - Lenvima (2) 660 	498 	33 	426 	287 	48 	235 	211 	11
Alliance Revenue - Reblozyl (3) 124 	* 	87 	* 	37 	*
Vaccines (4)
Gardasil / Gardasil 9 	5,428 	4,144 	31 	1,803 	1,605 	12 	3,624 	2,539 	43
ProQuad / M-M-R II / Varivax 	1,716 	1,626 	6 	1,337 	1,255 	6 	379 	371 	2
RotaTeq 	644 	593 	9 	427 	364 	17 	218 	229 	-5
Pneumovax 23 	457 	600 	-24 	280 	354 	-21 	177 	247 	-28
Vaqta 	134 	138 	-3 	72 	80 	-9 	62 	58 	6
Hospital Acute Care
Bridion 	1,244 	1,096 	13 	665 	545 	22 	579 	551 	5
Prevymis 	310 	270 	15 	136 	111 	23 	174 	159 	9
Dificid 	196 	115 	70 	184 	108 	70 	12 	7 	75
Primaxin 	185 	194 	-5 	1 	87 	185 	194 	-5
Noxafil 	180 	197 	-9 	39 	48 	-20 	141 	149 	-5
Invanz 	148 	157 	-6 	4 	(2) 	* 	144 	159 	-10
Cancidas 	138 	168 	-18 	5 	4 	27 	133 	164 	-19
Zerbaxa 	120 	(11) 	* 	64 	(5) 	* 	55 	(6) 	*
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 258 	248 	4 	244 	222 	10 	14 	26 	-47
Adempas (6) 181 	188 	-4 	181 	188 	-4
Virology
Lagevrio 	4,859 	* 	1,523 	* 	3,336 	*
Isentress / Isentress HD 	466 	590 	-21 	196 	222 	-12 	270 	368 	-27
Neuroscience
Belsomra 	199 	238 	-16 	60 	56 	7 	139 	183 	-24
Immunology
Simponi 	540 	619 	-13 	540 	619 	-13
Remicade 	163 	233 	-30 	163 	233 	-30
Diabetes (7)
Januvia 	2,252 	2,445 	-8 	958 	997 	-4 	1,294 	1,448 	-11
Janumet 	1,347 	1,449 	-7 	258 	244 	6 	1,089 	1,205 	-10
Other Pharmaceutical (8) 1,565 	1,589 	-1 	616 	637 	-3 	949 	950 	-
ANIMAL HEALTH 	4,320 	4,307 	- 	1,425 	1,363 	5 	2,894 	2,944 	-2
Livestock 	2,486 	2,503 	-1 	521 	508 	3 	1,965 	1,996 	-2
Companion Animals 	1,834 	1,804 	2 	904 	855 	6 	929 	948 	-2
Other Revenues (9) 1,307 	162 	* 	383 	192 	99 	925 	(30) 	*
* 200% or greater
Sum of U.S. plus international may not equal global due to rounding.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues
related to the receipt of upfront and milestone payments for out-licensed products were $156 million and $191 million on a global basis for September YTD 2022 and 2021, respectively.
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties and a milestone payment.
(4) Total Vaccines sales were $8,743 million and $7,417 million on a global basis for September YTD 2022 and 2021, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $3,836 million and $4,110 million on a global basis for September YTD 2022 and 2021, respectively.
(8) Includes Pharmaceutical products not individually shown above.
Table 3b
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
SEPTEMBER YEAR-TO-DATE 2022
(AMOUNTS IN MILLIONS)
(UNAUDITED)
7

-- 8 of 10 --

TOTAL PHARMACEUTICAL 	$14,107 	$12,756 	$12,963 	$39,826 	$9,238 	$9,980 	$11,496 	$30,714 	$12,039 	$42,754 	13 	30
United States 	6,773 	5,726 	6,620 	19,119 	4,294 	4,647 	5,670 	14,611 	5,790 	20,401 	17 	31
% Pharmaceutical Sales 	48.0% 	44.9% 	51.1% 	48.0% 	46.5% 	46.6% 	49.3% 	47.6% 	48.1% 	47.7%
Europe (1) 3,309 	2,677 	2,427 	8,412 	2,276 	2,404 	2,445 	7,124 	2,655 	9,780 	-1 	18
% Pharmaceutical Sales 	23.5% 	21.0% 	18.7% 	21.1% 	24.6% 	24.1% 	21.3% 	23.2% 	22.1% 	22.9%
China 	1,113 	1,355 	1,419 	3,887 	688 	944 	1,278 	2,910 	1,352 	4,262 	11 	34
% Pharmaceutical Sales 	7.9% 	10.6% 	10.9% 	9.8% 	7.4% 	9.5% 	11.1% 	9.5% 	11.2% 	10.0%
Japan 	965 	1,092 	653 	2,710 	607 	637 	614 	1,858 	771 	2,629 	6 	46
% Pharmaceutical Sales 	6.8% 	8.6% 	5.0% 	6.8% 	6.6% 	6.4% 	5.3% 	6.0% 	6.4% 	6.1%
Asia Pacific (other than China and Japan) 	786 	854 	702 	2,342 	437 	442 	450 	1,329 	488 	1,817 	56 	76
% Pharmaceutical Sales 	5.6% 	6.7% 	5.4% 	5.9% 	4.7% 	4.4% 	3.9% 	4.3% 	4.1% 	4.2%
Latin America 	435 	453 	511 	1,399 	353 	379 	434 	1,166 	421 	1,587 	18 	20
% Pharmaceutical Sales 	3.1% 	3.6% 	3.9% 	3.5% 	3.8% 	3.8% 	3.8% 	3.8% 	3.5% 	3.7%
Eastern Europe/Middle East/Africa 	450 	339 	360 	1,149 	357 	318 	362 	1,037 	278 	1,315 	-1 	11
% Pharmaceutical Sales 	3.2% 	2.7% 	2.8% 	2.9% 	3.9% 	3.2% 	3.1% 	3.4% 	2.3% 	3.1%
Canada 	189 	166 	166 	521 	160 	157 	164 	482 	167 	650 	1 	8
% Pharmaceutical Sales 	1.3% 	1.3% 	1.3% 	1.3% 	1.7% 	1.6% 	1.4% 	1.6% 	1.4% 	1.5%
Other 	87 	94 	105 	287 	66 	52 	79 	197 	117 	313 	33 	46
% Pharmaceutical Sales 	0.6% 	0.6% 	0.9% 	0.7% 	0.8% 	0.4% 	0.8% 	0.6% 	0.9% 	0.8%
2022 	2021 	% Change
MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
3Q September
YTD
1Q 	2Q 	3Q Sept
YTD 1Q 	2Q
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
3Q Sept
YTD 4Q 	Full Year
8

-- 9 of 10 --

OTHER (INCOME) EXPENSE, NET
3Q22 	3Q21
Sep YTD
2022
Sep YTD
2021
Interest income 	(40)	$ 	(7)	$ 	(62)	$ 	(27)	$
Interest expense 	244 	196 	727 	597
Exchange losses 	96 	46 	220 	202
Loss (income) from investments in equity securities, net (1) 371 	(683) 	1,361 	(1,535)
Net periodic defined benefit plan (credit) cost other than service cost 	(60) 	40 	(208) 	(159)
Other, net 	(182) 	(42) 	(462) 	(85)
Total 	429	$ 	(450)	$ 	1,576	$ 	(1,007)	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests
in investment funds are accounted for on a one quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
9

-- 10 of 10 --